RESEARCH ARTICLE

A Cytokine Signalling Network for the Regulation of Inducible Nitric Oxide Synthase Expression in Rheumatoid Arthritis

Poulami Dey1,2, Venugopal Panga1,2, Srivatsan Raghunathan1 *

1 Institute of Bioinformatics and Applied Biotechnology (IBAB), Biotech Park, Electronics City Phase I, Bengaluru 560 100, Karnataka, India, 2 Manipal University, Manipal, 576104, Karnataka, India

* srivatsan@ibab.ac.in

Abstract

In rheumatoid arthritis (RA), nitric oxide (NO) is implicated in inflammation, angiogenesis and tissue destruction. The enzyme inducible nitric oxide synthase (iNOS) is responsible for the localised over-production of NO in the synovial joints affected by RA. The pro- and anti-inflammatory cytokines stimulate the synovial macrophages and the fibroblast-like synoviocytes to express iNOS. Therefore, the cytokine signalling network underlying the regulation of iNOS is essential to understand the pathophysiology of the disease. By using information from the literature, we have constructed, for the first time, the cytokine signalling network involved in the regulation of iNOS expression. Using the differential expression patterns obtained by re-analysing the microarray data on the RA synovium and the synovial macrophages available in the Gene Expression Omnibus (GEO) database, we aimed to establish the role played by the network genes towards iNOS regulation in the RA synovium. Our analysis reveals that the network genes belonging to interferon (IFN) and interleukin-10 (IL-10) pathways are always up-regulated in the RA synovium whereas the genes which are part of the anti-inflammatory transforming growth factor-beta (TGF-β) signalling pathway are mostly down-regulated. We observed a consistent up-regulation of the transcription factor signal transducers and activators of transcription 1 (STAT1) in the RA synovium whereas the genes which are part of the anti-inflammatory transforming growth factor-beta (TGF-β) signalling pathway are mostly down-regulated. We observed a consistent up-regulation of the transcription factor signal transducers and activators of transcription 1 (STAT1) in the RA synovium whereas the genes which are part of the anti-inflammatory transforming growth factor-beta (TGF-β) signalling pathway. Interestingly, we found a consistent up-regulation of the iNOS interacting protein ras-related C3 botulinum toxin substrate 2 (RAC2) in the RA synovium as well as the macrophages. Importantly, we have constructed a model to explain the impact of IFN and IL-10 pathways on Rac2-iNOS interaction leading to over-production of NO and thereby causing chronic inflammation in the RA synovium. The interplay between STAT1 and RAC2 in the regulation of NO could have implications for the identification of therapeutic targets for RA.

Introduction

Rheumatoid arthritis (RA) is a systemic, polygenic, auto-immune inflammatory joint disease affecting about 1% of the world population [1]. The disease usually attacks the diarthrodial
joints of hands, feet, shoulder and knee. The aetiology of the disease is still unknown [2]. RA is characterized by chronic synovitis. Early synovitis can meet with one of the three fates: resolving synovitis, non-RA persistent synovitis or RA synovitis. Histopathological studies on synovial tissues have failed to characterize the early synovitis which could subsequently develop into RA synovitis [3]. The well-established association of cytokines with inflammation prompted an experimental investigation and characterization of differential expressions of cytokines in the affected synovial fluid and tissues, including blood, in different groups of patients. Mainly, immunoassays and PCR-based techniques are used to quantify the presence of cytokines and their mRNAs respectively in the sample tissues. We have summarized the results on relative change in the cytokine concentrations in the affected tissues of pre-RA and RA patients published in literature (Table 1).

Table 1 corroborates a significant rise of the pro-inflammatory as well as some of the anti-inflammatory cytokines such as interleukin-4 (IL-4) and IL-10 in the serum of pre-RA and RA patients. The role of anti-inflammatory cytokines is to curb the pro-inflammatory cytokine responses. However, it is observed that RA synovitis prevails in spite of an increase in the concentration of anti-inflammatory cytokines. Conceivably, the concentration of anti-inflammatory cytokines may not be high enough to balance the pro-inflammatory responses, leading to RA synovitis.

The interplay of the pro- and anti-inflammatory cytokines induces the production of enzyme iNOS in the affected tissues of RA patients [1]. The enzyme iNOS catalyses the formation of nitric oxide (NO). Strong expression of iNOS has been observed in the synovium and cartilage of RA patients while the normal synovium from healthy individuals is completely devoid of it [9, 10]. Grabowski et al [9] have established that CD68+ macrophages of the synovial lining and fibroblasts are the source of iNOS expression in the RA synovium. Sakurai et al [10] have shown a strong correlation between the numbers of iNOS+ synoviocytes and the NO levels in the RA synovium. The concentrations of NO and nitrite, which is a stable metabolic form of NO, are significantly higher in the serum and the synovial tissues of RA patients than in healthy controls [11, 12]. The constitutively expressed nitric oxide synthases, endothelial NOS (eNOS) and neuronal NOS (nNOS), are involved in the maintenance of the physiological
concentrations of NO. However, iNOS once induced by cytokines produces high concentrations of NO for a prolonged time period in affected RA tissues [13].

Ex-vivo experimental studies on human RA synoviocytes have shown that a combination of IL-1β, tumour necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) induces a significant increase in the production of iNOS and nitrite [9, 10, 14]. It is established that transforming growth factor-beta (TGF-β) and IL-4 down-regulate iNOS expression in murine macrophages [15, 16]. Active RA patients, on treatment with the IL-6 antagonist tocilizumab, show a prominent decrease in serum nitrite concentration [17]. It has been proposed that IL-10 is responsible for iNOS expression during the pathogenesis of RA [1].

To summarize, multiple studies on affected tissues of RA have established the following: (a) the existence of an imbalance in the expression of pro- and anti-inflammatory cytokines, (b) increased expression of iNOS and NO and (c) regulation of the expression of iNOS and consequently NO by various pro- and anti-inflammatory cytokines.

Wu et al have published a comprehensive molecular interaction map of RA consisting of 273 proteins and their associated genes [18]. However, the regulation of iNOS expression by cytokine signalling pathways in RA is not present in their network. In our study, in order to explain the role of downstream signalling molecules of various cytokine pathways that regulate iNOS in RA, we first constructed an elaborate signalling network of cytokines such as IL-1β, TNF-α, IL-6, IFN-γ, TGF-β, IL-4 and IL-10 using data on interactions between the signal-transducers reported in the literature. To the best of our knowledge, such a comprehensive cytokine signalling network regulating iNOS expression is created for the first time. Further, to establish the role of these network genes in RA, we have re-analysed the available microarray data on the disease. Our analysis reveals a possible mechanism that leads to the over-production of NO catalysed by iNOS in the RA synovium.

**Materials and Methods**

**Construction of the cytokine signalling network**

The cytokine signalling network which regulates the expression of iNOS in mammalian cells was constructed based on an extensive literature survey using PubMed. From the published results of experiments on rat, mouse and human cell lines, the required information on the regulation of iNOS were retrieved. We have used 25 search terms to retrieve 57 articles which were referred to construct the network. For example, the search term (rheumatoid OR rheumatic OR arthritis OR arthritides) AND (cytokines OR cytokine OR cytokinin OR pathogenesis) with a filter of “Title” for search fields was used in PubMed to retrieve references 1–8 in this study. Similarly, another 24 search terms were used to retrieve the articles related to the construction of the network. The complete list of the search terms and the corresponding retrieved references are included in S1 File. The information includes protein interactions, regulations and cross-talks between downstream signal transducers and transcription factors induced by cytokine stimulations [13, 16, 19–50]. Using this information, the cytokine signalling network regulating iNOS expression was constructed in CellDesigner 4.4. This network consists of proteins that are encoded by 106 genes. While constructing the network, a cell compartment enclosing a nucleus compartment was created. The nodes (proteins, protein complexes, receptors, mRNA and genes) were added in the appropriate compartments as given in the literature. The interactions (activation, inhibition, state transition, ubiquitination, transportation, transcription and translation) were then added to connect the nodes in the network. In case of an interaction where multiple molecules are responsible for the interaction process such as ubiquitination, the multiple lines are joined using “and” option in CellDesigner. The dotted lines were used to represent the interactions that were stated to be prevalent by unknown mechanism.
Microarray data analysis

In GEO database, the search term (Rheumatoid OR arthritis OR arthritides OR joint OR synovium OR synovial) AND (affymetrix) was used with filters Homo sapiens, Series and Expression profiling by array. This search resulted in 156 hits. By reading the summary of each paper, we identified the studies which involved both RA synovial samples vs. normal controls and synovial macrophage samples vs. normal macrophage controls. This resulted in seven Affymetrix microarray datasets related to human RA patients (Table 2). Six of them correspond to synovial membrane and one corresponds to synovial macrophages. The analysis was carried out using the Bioconductor library in R statistical package [51]. For each of the seven datasets, the following analysis procedure was adapted: (i) The probe summarization was carried out using two of the standard normalization algorithms for Affymetrix data, namely MAS5 and RMA (ii) For each of the two summarization procedures, the differential expression of the genes between RA and control groups was computed using two sample independent t-test (iii) In order to reduce the false discovery rate, the p-values of the genes with fold changes greater than 0.5 or less than -0.5 in log2-scale were subjected to Benjamini-Hochberg (BH) correction. The genes which met the criterion of BH-corrected p-values < 0.1 were considered to be differentially expressed.

In a given synovial data set, a gene was considered if it is differentially expressed in the same direction (up or down regulation) in both the normalization methods. In case a gene is differentially expressed in only one of the normalization methods and not in the other, it was considered only if it is expressed in the same direction in any other dataset in the complementary normalization method. For example, if a gene in dataset one expressed only in MAS5, it is required to be expressed in the same direction in any other dataset under RMA normalization.

Since there was only one macrophage data set, a gene was considered only if it is differentially expressed in the same direction (up or down regulation) in both the normalization methods.

In the resulting data, we looked at the 106 genes that are part of our cytokine network. For each gene, the number of datasets in which it was selected out of the six analysed was found.

The expression levels of the selected genes in the synovial and the macrophage datasets are presented in tabular form. In the case of synovial data, we have presented the maximum of the six up/down regulated values under each normalization.

Results

The cytokine signalling network regulating iNOS expression

In this study, the signalling pathways of the cytokines leading to the regulation of the transcription factors or modulator proteins associated with iNOS expression are consolidated into a

Table 2. Gene expression datasets used in this study.

| Sample Origin     | Sample Type and Number | GSE ID     | Platform                          | Ref. |
|-------------------|------------------------|------------|-----------------------------------|------|
| Synovial Tissue   | 5 RA, 5 Normal         | GSE 1919   | Affymetrix [HG-U95A]              | [52] |
| Synovial Membrane | 5 RA, 9 Normal         | GSE7307    | Affymetrix [HG-U133-Plus-2]       |      |
| Synovial Membrane | 12 RA, 9 Normal [U133A], 12 RA, 4 Normal [U133B] | GSE12021   | Affymetrix [HG-U133A] & Affymetrix [HG-U133B] | [53] |
| Synovial Membrane | 13 RA, 10 Normal       | GSE55457   | Affymetrix [HG-U133A]             | [54] |
| Synovial Membrane | 10 RA, 10 Normal       | GSE55235   | Affymetrix [HG-U133A]             | [54] |
| Macrophages       | 5 RA synovial fluid macrophages, 3 blood-derived normal macrophages | GSE10500   | Affymetrix [HG-U95Av2]            | [55] |

doi:10.1371/journal.pone.0161306.t002
network (Fig 1). The cytokines TNF-α, IL-1β, IFN-γ, IL-10, IL-4, IL-6 and TGF-β are involved in the activation of transcription factors such as NF-κB, STAT1, IRF1, STAT3, STAT6, Oct-1, C/EBPβ and AP-1 [16, 23–25, 31]. The promoter region of human iNOS shows multiple binding sites for these transcription factors [13, 19, 34]. The cytokine signalling network includes a) NF-κB activation by TNF-α, IL-1β, IFN-γ and TGF-β, b) STAT1 activation by TGF-β, IFN, TNF-α and IL-1β, c) STAT1, STAT3 and STAT6 activation by IL-10, IL-6 and IL-4, d)
regulation of Smad proteins by TGF-β e) activation of p300, C/EBPβ, AP-1 and Oct-1 by IFN-γ, TNF-α and IL1-β and f) regulation of iNOS expression by the signal transducers. The detailed description of the constructed signalling network regulating iNOS expression is included in S2 File.

Role of the network genes towards iNOS regulation in RA synovium from gene expression data

The results from the differential expression analysis of microarray datasets on RA synovial tissue are used to explain the functional roles of the network genes played in the regulation of iNOS as described below.

Differential expression of STAT1 and IFN, IL-10 and IL-6 signalling genes in the RA synovium. Cytokines such as IFN-γ, IFN-α, IFN-β, IL-10 and IL-6 are involved in the activation of STAT1. The maximum fold changes of the pathway genes from our microarray data analysis are tabulated in Tables 3 and 4. The analysis of the RA synovial datasets leads to the following three insights.

(i) Consistent up-regulation of STAT1 in the RA synovium: The up-regulation of STAT1 in the RA synovium is experimentally observed by Kraan et al [56]. In agreement with this, our analysis confirmed an increased level of STAT1 in all the synovial datasets (Fig 2). The maximum fold-change of STAT1 up-regulation was observed as 3.15 in log2 scale (Table 4).

Table 3. The maximum fold changes of the pathway genes corresponding to TNF-α, IL-1β pathways and few other transcription factors from our microarray data analysis.

| Genes   | Up Fold Change (on log2 scale) | Down Fold Change (on log2 scale) |
|---------|--------------------------------|----------------------------------|
|         | MAS5 RMA                        | Down Fold Change (on log2 scale) |
| FADD    | 0.87 0                          | -1 -0.71                         |
| CASP8   | 1.16 1.25                       | -0.55 -0.5                       |
| TNFRSF1B| 1.36 0.92                       | -0.66 -0.58                      |
| BIRC3   | 2.34 2.07                       | -1.6 -1.32                       |
| TRAF5   | 0.74 0.72                       | -1.36 -1.32                      |
| RELA    | 0 0                            | -0.99 -0.5                       |
| NFKB1   | 0 0                            | -0.77 -0.74                      |
| IKBKB   | 0 0                            | -0.93 -1.11                      |
| NFKBIA  | 0 0                            | -1.28 -1.12                      |
| TNFAIP3 | 1.72 1.78                       | -2.89 -1.7                       |
| CYLD    | 1.04 0.87                       | -0.93 -1.11                      |
| RNF11   | 0 0                            | -1.28 -1.12                      |
| IL1B    | 0 0                            | -1.4 -1.12                       |
| IL1RN   | 1.45 1.2                        | -1.4 -1.12                       |
| IL1R1   | 1.14 0                          | -0.93 -1.11                      |
| IL1RAP  | 0 0                            | -0.68 -0.68                      |
| MYD88   | 0.56 0.7                        | -0.68 -0.68                      |
| PELI1   | 0 0                            | -0.93 -1.11                      |
| PELI2   | 0 0                            | -0.93 -1.11                      |
| IRAK4   | 0.61 0.6                        | -0.93 -1.11                      |
| MAPK14  | 0 0                            | -0.68 -0.68                      |
| TAB3    | 0.57 0.66                       | -0.88 -0.9                       |
| POU2F1  | 0 0                            | -0.88 -0.9                       |
| CEBPB   | 0 0                            | -0.88 -0.9                       |
(ii) Consistent up-regulation of IFN and IL-10 pathway genes in the RA synovium: Besides STAT1, the other transcription factors like STAT2, IRF1, IRF9 and IRF8 which are part of IFN-mediated iNOS expression are up-regulated in at least one or more RA synovial datasets (Fig 2). Moreover, the JAK kinases JAK2 and TYK2 are also up-regulated in the synovial datasets. Further, the IFN type-I receptors and IL-10 receptors are up-regulated in two or more synovial datasets. The only IFN cytokine gene that is up-regulated is IFNA1. These genes which mediate IFN type-I, type-II and IL-10 signalling are never down-regulated in any of the synovial datasets. Additionally, SOCS1 which is induced by transcription factors STAT1 and IRF1, is also never down-regulated. The fold-changes of these genes in log2 scale are given in Table 4.

### Table 4. The maximum fold changes of the pathway genes corresponding to IFN, IL-10, IL-6, TGF-β pathways and AP-1 transcription factor from our microarray data analysis.

| Genes       | Up Fold Change (on log2 scale) | Down Fold Change (on log2 scale) |
|-------------|--------------------------------|----------------------------------|
|             | MAS5 RMA                       | MAS5 RMA                         |
| IFNA1       | 1.12 0.99                      | 0 0                              |
| IFNB1       | 0 0                            | 0 0                              |
| IFNAR1      | 0.9 0.57                       | 0 0                              |
| IFNAR2      | 1.2 1.36                       | 0 0                              |
| JAK2        | 1.67 1.13                      | 0 0                              |
| TYK2        | 1.18 0.83                      | 0 0                              |
| STAT1       | 2.81 3.15                      | 0 0                              |
| STAT2       | 1.21 1.03                      | 0 0                              |
| IRF1        | 1.31 1.43                      | 0 0                              |
| IRF8        | 1.03 1.19                      | 0 0                              |
| IRF9        | 0.7 0.66                       | 0 0                              |
| IL10RA      | 1.36 1.18                      | 0 0                              |
| IL10RB      | 1.03 0.87                      | 0 0                              |
| SOCS1       | 1.48 1.13                      | 0 0                              |
| IL6         | 0 0                            | -2.39 -2.6                       |
| IL6ST       | 0 0                            | -1.17 -0.8                       |
| STAT3       | 0 0                            | -0.54 -1.4                       |
| EGFR        | 0 0                            | -1.91 -2.22                      |
| SOCS3       | 0.81 0                         | -2.44 -2.28                      |
| PTPN6       | 1.64 1.14                      | 0 0                              |
| PTPN11      | 0 0                            | -1.6 -1.04                       |
| FOS         | 0 0                            | -2 -2.04                        |
| JUND        | 0 0                            | -0.98 -2.09                      |
| FOSL2       | 0 0                            | -2.73 -2.27                      |
| TGFβ1       | 2.53 1.94                      | 0 0                              |
| LTBP1       | 0 0                            | -1.04 -0.69                      |
| LTBP2       | 0.69 0.72                      | 0 0                              |
| TGFBR2      | 0 0                            | -2.95 -1.29                      |
| THBS1       | 0 0                            | -1.31 -1.65                      |
| SMAD2       | 1.08 0.72                      | -0.53 -0.7                       |
| SMAD3       | 0.88 0.79                      | -1.07 -1.03                      |
| SMAD7       | 0 0                            | -1.25 -1.2                       |
| NFE2L1      | 0 0                            | -1.04 -0.81                      |

doi:10.1371/journal.pone.0161306.t004
(iii) Consistent down-regulation of IL-6 pathway genes in the RA synovium: The gene for IL-6 receptor (IL6ST) is down-regulated in five synovial microarray datasets. The cytokine IL-6 and the transcription factor STAT3 are down-regulated in at least one dataset (Fig 2). EGFR which enhances iNOS expression by binding to STAT3 is also down-regulated in five datasets. None of these genes is up-regulated in any of the synovial datasets. SOCS3, the feedback inhibitor of IL-6 signalling is mostly down-regulated in five datasets and up-regulated in one dataset.
Thus the results show an increased expression of genes in IFN and IL-10 pathways and decreased expression of genes in IL-6 pathway (Fig 2). As described earlier, IFN, IL-10 and IL-6 cytokines are involved in the activation of STAT1. The increased expression of IFN and IL-10 pathway genes suggests that STAT1 is likely to be activated by IFN and IL-10 pathways in the RA synovium.

**Differential expression of TGF-β signalling genes in the RA synovium.** Most of the genes of the TGF-β pathway are down-regulated in the RA synovium (Fig 3). The maximum fold changes of these genes across all the synovial datasets are reported in Table 4. The genes TGFBR2, THBS1, SMAD7, TCF11 and LTBP1 are down-regulated in at least one dataset and are not up-regulated in any of the synovial datasets. The modulator proteins, Smad3 is up-regulated in one dataset and is down-regulated in four datasets whereas Smad2 is up-regulated in one dataset and is down-regulated in one dataset. TGFBR1 and LTBP2 are up-regulated in three and two datasets respectively.
It is known that TGF-β and Smad3 facilitate inhibition of iNOS expression in RA [15, 20]. In this study, we have observed an up-regulation of the anti-inflammatory cytokine TGF-β (TGFB1). However, the downstream signal transducers of this pathway are mostly down-regulated. The transcription factor TCF11 which represses iNOS expression is also down-regulated. The decreased expression of the anti-inflammatory TGF-β pathway genes suggest that iNOS repression by TGF-β is not very prominent in the RA synovium.

Fig 4. The number of the synovial datasets in which the pathway genes corresponding to TNF-α and IL-1β pathways are differentially expressed. The green bars represent up-regulation of the genes in the datasets whereas the red bars represent their down-regulation.

doi:10.1371/journal.pone.0161306.g004
Differential expression of TNF-α and IL-1β signalling genes in the RA synovium. The results of our microarray data analysis show a mixed regulation (up- and down-) of the genes involved in the TNF-α and IL-1β signalling pathways (Fig 4 and Table 3). The feedback regulator TNFAIP3 (A20) which negatively regulates TNF-α and IL-1β signalling is up-regulated in two datasets and is down-regulated in one dataset. Another feedback regulator of TNF-α dependent NF-κB activation, CYLD is up in three datasets and is never down in any of the datasets. Additionally, the IκB kinase IKKB and the NF-κB genes NFKB1 (p50) and RELA (p65) are down-regulated.

Differential expression of other transcription factors in the RA synovium. The genes which are part of the transcription factor AP-1, FOS, FOSL2 (Fra2), JUN and JUND are down-regulated in at least three or more synovial datasets and are never up in any of the datasets. The genes of the other transcription factors Oct-1 and C/EBPβ which are involved in enhancement of iNOS expression are down in the RA synovial datasets (Fig 5, Tables 3 and 4).

**AP-1, Oct-1 and C/EBPβ genes**

![Graph showing the number of synovial datasets in which pathway genes corresponding to transcription factors AP-1, Oct-1 and C/EBPβ are differentially expressed. The green bars represent up-regulation of the genes in the datasets whereas the red bars represent their down-regulation.](https://doi.org/10.1371/journal.pone.0161306.g005)

Fig 5. The number of the synovial datasets in which the pathway genes corresponding to transcription factors AP-1, Oct-1 and C/EBPβ are differentially expressed. The green bars represent up-regulation of the genes in the datasets whereas the red bars represent their down-regulation.
Differential expression of the network genes in the RA macrophages. The results of our microarray data analysis on the macrophage dataset is presented in Table 5. In contrast to the expression status in synovial datasets, the genes that were up-regulated in the macrophage dataset are janus kinase JAK1, feedback regulator SOCS1, IL10 receptor IL10RB, TGF-β signal modulators SMAD3 and SMAD7, the kinase p38MAPK and the transcription factor C/EBPβ. In spite of these differences, the transcription factor STAT1 which is up-regulated in the synovial dataset is also up-regulated in the macrophage dataset.

Effects of medical therapies received by RA patients on gene expression data. Each RA patient belonging to different synovial and macrophage datasets underwent different combinations of medical therapies. The medical therapies received by the patients are disease modifying anti-rheumatic drug (DMARD), non-steroidal anti-rheumatic drug (NSARD), Azulfidine (AZ), Prednisolone (PS), Methotrexate (MTX), Cox-2 inhibitor (CX), Quensyl (QS), Tilidin (T) and non-steroidal anti-inflammatory drug (NSAID). The details of the medical therapies are listed in Table 6. It is seen that within a dataset, some patients received same combination of medical therapies whereas others received different combinations. To test if the gene expressions are influenced by these medical therapies, the samples treated with different combinations of medical therapies were hierarchically clustered based on the expression of the network genes in these samples. Except for GSE1919, it is observed that the gene expressions are not influenced by the type of the medical therapies received by the RA patients (Figs 6–12).

Table 5. The maximum fold changes of the pathway genes in macrophage dataset from our microarray data analysis.

| Genes      | Up Fold Change (on log2 scale) | Down Fold Change (on log2 scale) |
|------------|-------------------------------|----------------------------------|
|            | MAS5 RMA                       | MAS5 RMA                         |
| TNFRSF1B   | 1.62 1.02                     | 0 0                              |
| RIPK1      | 0 0                           | -0.97 -0.83                      |
| MAP3K3     | 0 0                           | -1.63 -1.58                      |
| CFLAR      | 2.42 1.49                     | 0 0                              |
| MAPK14     | 1.14 1.15                     | 0 0                              |
| CEBPB      | 0.92 0.82                     | 0 0                              |
| TAX1BP1    | 0.83 0.7                      | 0 0                              |
| TAB1       | 0 0                           | -0.95 -0.89                      |
| TNFAIP3    | 1.91 1.83                     | 0 0                              |
| IL1B       | 0 0                           | -0.81 -0.68                      |
| IL1R2      | 2.05 1.68                     | 0 0                              |
| JAK1       | 1.4 1.32                      | 0 0                              |
| STAT1      | 1.12 1.58                     | 0 0                              |
| SOCS1      | 0 0                           | -0.9 -0.69                       |
| FOS        | 1.77 0.81                     | 0 0                              |
| IL10RB     | 0 0                           | -1.46 -1.21                      |
| IL6ST      | 0 0                           | -0.84 -0.75                      |
| STAT6      | 0 0                           | -1.45 -0.95                      |
| SMAD3      | 0.89 0.8                      | 0 0                              |
| SMAD4      | 0 0                           | -0.63 -0.53                      |
| SMAD7      | 0.82 0.98                     | 0 0                              |

doi:10.1371/journal.pone.0161306.t005
Table 6. Medical therapies received RA patients.

| Dataset      | Patients | Medical Therapies                  |
|--------------|----------|------------------------------------|
| GSE1919      | RA1      | DMARD                              |
|              | RA2      | DMARD                              |
|              | RA3      | DMARD + NSAID                      |
| GSE7307      | RA1      | no therapy used                    |
|              | RA2      | no therapy used                    |
|              | RA3      | no therapy used                    |
|              | RA4      | no therapy used                    |
|              | RA5      | no therapy used                    |
| GSE12021A    | RA1      | NSARD + Azulfidine + Prednisolone  |
|              | RA2      | NSARD + MTX + Prednisolone         |
|              | RA3      | NSARD + MTX + Prednisolone         |
|              | RA4      | NSARD + Azulfidine + Prednisolone + MTX |
|              | RA5      | NSARD + MTX + Prednisolone         |
|              | RA6      | NSARD + Azulfidine + Prednisolone  |
|              | RA7      | MTX + Prednisolone                 |
|              | RA8      | NSARD                              |
|              | RA9      | NSARD + Prednisolone               |
|              | RA10     | NSARD + Prednisolone               |
|              | RA11     | COX-2 inhibitor + Prednisolone + Quensyl |
|              | RA12     | NSAID + Tilidin + Prednisolone     |
| GSE12021B    | RA1      | NSARD + Azulfidine + Prednisolone  |
|              | RA2      | NSARD + MTX + Prednisolone         |
|              | RA3      | NSARD + MTX + Prednisolone         |
|              | RA4      | NSARD + Azulfidine + Prednisolone + MTX |
|              | RA5      | NSARD + MTX + Prednisolone         |
|              | RA6      | NSARD + Azulfidine + Prednisolone  |
|              | RA7      | MTX + Prednisolone                 |
|              | RA8      | NSARD                              |
|              | RA9      | NSARD + Prednisolone               |
|              | RA10     | NSARD + Prednisolone               |
|              | RA11     | COX-2 inhibitor + Prednisolone + Quensyl |
|              | RA12     | NSAID + Tilidin + Prednisolone     |
| GSE55457     | RA1      | NSARD + Azulfidine + Prednisolone  |
|              | RA2      | NSARD + MTX + Prednisolone         |
|              | RA3      | NSARD + MTX + Prednisolone         |
|              | RA4      | NSARD + Azulfidine + Prednisolone + MTX |
|              | RA5      | NSARD + MTX + Prednisolone         |
|              | RA6      | NSARD + Azulfidine + Prednisolone  |
|              | RA7      | MTX + Prednisolone                 |
|              | RA8      | NSARD                              |
|              | RA9      | NSARD + Prednisolone               |
|              | RA10     | no therapy used                    |
|              | RA11     | NSARD + Prednisolone               |
|              | RA12     | COX-2 inhibitor + Prednisolone + Quensyl |
|              | RA13     | NSAID + Tilidin + Prednisolone     |

GSE55235  
RA1  Therapies not mentioned  

(Continued)
Proposed role of STAT1 in the over-production of NO in the RA synovium

Our analysis confirmed an increased level of STAT1 in the synovium as well as the synovial macrophages of RA patients. Therefore we wanted to check if STAT1 interacts with any other iNOS interacting proteins that regulate the production of NO catalysed by iNOS. To find the answer, we have retrieved all the iNOS interacting proteins from three protein-protein interaction databases namely Pathway Commons, HPRD and InnateDB [57, 58, 59]. Among the iNOS-interacting proteins which are not part of the cytokine signalling network, only the RAC2 gene is up-regulated in both the macrophage and the synovial datasets. Hu et al [60] have shown that the activated STAT1 fixes Rac in a GTP-bound state (Rac-GTP) in macrophages. Rac2-GTP enhances the production of IFN-γ by inducing the IFN-γ promoter via activation of the transcription factors p38 and NF-κB [61]. The elevated expressions of STAT1 and RAC2 in our analysis demonstrate an increased possibility of Rac2 activation by activated STAT1 in the RA synovium and the synovial macrophages. This paves the way for the formation of a positive feedback loop resulting in an increased production of the pro-inflammatory cytokine IFN-γ and subsequent activation of STAT1 and Rac2 (Fig 13). The interaction between Rac2 and iNOS is crucial for Rac2 mediated NADPH oxidase activation. NADPH oxidase induces reactive oxygen species (ROS) production. ROS potentiates the expression of iNOS by activating JAK2/ IRF1 pathway [62]. Up-regulation of JAK2 and IRF1 observed in our analysis supports the possibility of ROS mediated expression of iNOS in the RA synovium. Thus, the activation of Rac2 by activated STAT1 also triggers the second positive feedback loop for enhanced production of ROS and iNOS in the RA affected synovium (Fig 13). Kuncewicz et al have stated that the balance between GTP- and GDP-bound Rac2 might play a role in the kinetics or stability of Rac2 interaction with iNOS [63]. It is experimentally shown that Rac2-GTP interacts with iNOS protein to generate high amounts of NO, ROS and reactive nitrogen species (RNS) in human cells [62]. NO induces a depletion of ATP leading to necrosis. Increased necrosis facilitates release of more antigen [64]. This leads to a chronic inflammation in the RA synovium. NO stimulates oxidative stress in the RA synovium. It reacts with superoxide to form peroxynitrite which is responsible for pro-inflammatory effects in the affected RA synovium. NO is also responsible for an up-regulation of the matrix metalloproteinases.

Table 6. (Continued)

| Dataset   | Patients | Medical Therapies     |
|-----------|----------|-----------------------|
| RA2       |          | Therapies not mentioned |
| RA3       |          | Therapies not mentioned |
| RA4       |          | Therapies not mentioned |
| RA5       |          | Therapies not mentioned |
| RA6       |          | Therapies not mentioned |
| RA7       |          | Therapies not mentioned |
| RA8       |          | Therapies not mentioned |
| RA9       |          | Therapies not mentioned |
| RA10      |          | Therapies not mentioned |
| GSE10500  | RA1      | no therapy used       |
|           | RA2      | no therapy used       |
|           | RA3      | no therapy used       |
|           | RA4      | no therapy used       |
|           | RA5      | no therapy used       |

doi:10.1371/journal.pone.0161306.t006
which are the key players for joint destruction in RA [65]. Thus, we have constructed a model of IFN/IL-10 pathway mediated chronic inflammation via elevated levels of NO in the RA synovium.

Fig 6. Hierarchical clustering of the individual samples based on the expressions of the network genes in GSE1919. In this dataset, three RA patients and five controls were considered for the clustering after eliminating two pooled RA samples. The RA and the control samples clustered into separate groups. The medical therapies received by the patients are indicated in the figure.

doi:10.1371/journal.pone.0161306.g006
Fig 7. Hierarchical clustering of the individual samples based on the expressions of the network genes in GSE7307. In this dataset, five RA patients and nine controls were considered for the clustering. The RA and the control samples clustered into separate groups.

doi:10.1371/journal.pone.0161306.g007
Fig 8. Hierarchical clustering of the individual samples based on the expressions of the network genes in GSE12021 (U133 A). In this dataset, twelve RA patients and nine controls were considered for the clustering. One RA sample clustered together with the control samples whereas the other RA samples clustered separately. The medical therapies received by the patients are indicated in the figure. The medical therapies received by the patients are non-steroidal anti-rheumatic drug (NSARD), Azulfidine (AZ), Prednisolone (PS), Methotrexate (MTX), Cox-2 inhibitor (CX), Quensyl (QS), Tilidin (T) and non-steroidal anti-inflammatory drug (NSAID).

doi:10.1371/journal.pone.0161306.g008
In this study, we have constructed the cytokine signalling network underlying the regulation of iNOS in the RA synovium. The network includes seven cytokines among which TNF-α, IL-1β and IFN-γ are known to be pro-inflammatory and the remaining four cytokines namely IL-6, TGF-β, IL-10 and IL-4 are known to be pleiotropic in many diseases. But studies on RA have shown IL-6 mainly as pro-inflammatory whereas TGF-β, IL-10 and IL-4 as anti-inflammatory.

As far as the regulation of iNOS is concerned, experiments in literature have shown the cytokines TGF-β and IL-4 are known to play contrasting roles. While constructing the network, although we have included certain relevant paths by which TGF-β can up- as well as down-regulate iNOS, the paths by which IL-4 up-regulates iNOS have not been included. We acknowledge this as a limitation in our network construction. Though the number of cytokines and the transcription factors included in the network is limited compared to the huge number of

Fig 9. Hierarchical clustering of the individual samples based on the expressions of the network genes in GSE12021 (U133 B). In this dataset, twelve RA patients and four controls were considered for the clustering. One RA sample clustered together with the control samples. The medical therapies received by the patients are indicated in the figure. The medical therapies received by the patients are non-steroidal anti-rheumatic drug (NSARD), Azulfidine (AZ), Prednisolone (PS), Methotrexate (MTX), Cox-2 inhibitor (CX), Quensyl (QS), Tilidin (T) and non-steroidal anti-inflammatory drug (NSAID).

doi:10.1371/journal.pone.0161306.g009

Discussion

In this study, we have constructed the cytokine signalling network underlying the regulation of iNOS in the RA synovium. The network includes seven cytokines among which TNF-α, IL-1β and IFN-γ are known to be pro-inflammatory and the remaining four cytokines namely IL-6, TGF-β, IL-10 and IL-4 are known to be pleiotropic in many diseases. But studies on RA have shown IL-6 mainly as pro-inflammatory whereas TGF-β, IL-10 and IL-4 as anti-inflammatory. As far as the regulation of iNOS is concerned, experiments in literature have shown the cytokines TGF-β and IL-4 are known to play contrasting roles. While constructing the network, although we have included certain relevant paths by which TGF-β can up- as well as down-regulate iNOS, the paths by which IL-4 up-regulates iNOS have not been included. We acknowledge this as a limitation in our network construction. Though the number of cytokines and the transcription factors included in the network is limited compared to the huge number of
Hierarchical clustering of the individual samples based on the expressions of the network genes in GSE55457. In this dataset, thirteen RA patients and ten controls were considered for the clustering. One RA sample clustered together with the control samples whereas the other RA samples clustered separately. The medical therapies received by the patients are indicated in the figure. The medical therapies received by the patients are non-steroidal anti-rheumatic drug (NSARD), Azulfidine (AZ), Prednisolone (PS), Methotrexate (MTX), Cox-2 inhibitor (CX), Quensyl (QS), Tildin (T) and non-steroidal anti-inflammatory drug (NSAID).

doi:10.1371/journal.pone.0161306.g010
Hierarchical clustering of the individual samples based on the expressions of the network genes in GSE55235. In this dataset, ten RA patients and ten controls were considered for the clustering. The RA and the control samples clustered into separate groups. The medical therapies received by the RA patients are not specified in this dataset.

doi:10.1371/journal.pone.0161306.g011
Fig 12. Hierarchical clustering of the individual samples based on the expressions of the network genes in GSE10500. In this dataset, five RA patients and three controls were considered for the clustering. The RA and the control samples clustered into separate groups.

doi:10.1371/journal.pone.0161306.g012
Fig 13. The proposed model by which IFN/IL-10 pathway mediates chronic inflammation in the RA synovium by elevating NO. The coloured box with the black boundary is a representative cell in the RA synovium. The Y-shaped
cytokines involved in the RA pathology, it is the most comprehensive network to date for describing the iNOS regulation.

Using the available microarray datasets on RA synovium and macrophages in GEO database, the differential expressions of the network genes are measured. The differential expressions are analysed to establish the functional roles of the network genes played in the regulation of iNOS. Most of the IFN and IL-10 pathway genes including the transcription factors STAT1, STAT2, IRF1 belonging to the network are always up-regulated in the RA synovium. An elevated expression of the transcription factor STAT1 is identified to be consistent in the RA synovium and the synovial macrophages. Additionally, the expressions of the most of the network genes belonging to the pathway signalled by the anti-inflammatory cytokine TGF-β are decreased in the RA synovium. The network genes belonging to TNF-α and IL-1β pathways are observed to be regulated in a mixed (up- and down-) nature.

We have observed that the expression of SOCS1, a negative regulator of JAK/STAT pathway is increased in the RA synovium. The published literature supports the activation of JAK/STAT pathway in RA [66, 67]. SOCS1, a negative regulator, is also one of the target genes of this pathway. SOCS1, being a target gene of the JAK/STAT pathway, is expected to be up-regulated while the pathway is active. In support of this, Isomaki et al have reported the up-regulation of SOCS1 in the RA synovial membrane over healthy controls [68]. The cytokines such as IFN, IL-10 and IL-6 activate the JAK/STAT pathway. IFN and IL-10 pathway genes such as the cytokine receptors, JAK2, TYK2, STAT1 and IRF1 are observed to be up-regulated in our analysis. Therefore it is highly likely that the JAK/STAT pathway is active in the RA synovium. In relation to this, in our analysis we have observed elevated expression of the STAT1 target genes (Table 7). This observation provides strong evidence that the JAK/STAT pathway is definitely active despite the up-regulation of SOCS1.

The pro-inflammatory cytokine IL-6 is usually elevated in RA affected synovial tissue. Our analysis shows no up-regulation of IL-6 in one of the datasets while it is not differentially expressed in the others. An experimental study by Chen et al confirmed no up-regulation of IL-6 in four out of seven and six out of eight synovial tissue and fluid samples from RA patients compared to healthy controls [69]. It is possible that in some cases IL-6 might not be up-regulated in the RA synovium. Additionally, IL-6R is not up-regulated in the analysis. IL-6 receptors are expressed by neutrophils, monocytes/macrophages and some lymphocytes which infiltrate the RA synovium exhibiting chronic inflammation. Though the resident synoviocytes do not express IL-6R, these cells carry forward the IL-6 signalling by an alternative trans-signalling pathway [70, 71]. Usually, the transition from acute to chronic inflammation in RA is controlled by IL-6. It is not known whether the synovium samples collected from the RA patients belonging to various data sets considered for this study manifested chronic inflammation. This is one of the limitations of this study.

The IL-6 receptor (gp130), on binding to IL-6, activates JAK1, JAK2 and TYK2. The JAKs promote activation of STAT3 which relocates to the nucleus to turn on STAT3-responsive genes. Earlier studies have shown the presence of activated STAT3 in the RA synovial tissues although the expression of STAT3 was not elevated [72]. In addition to JAK3, STAT3 can also be activated by the kinases JAK1 and TYK2 that are activated by IL-10 signalling pathway. In this analysis, we have observed an up-regulation of IL-10 pathway genes including TYK2. Though STAT3 is not up-regulated, it is likely that the phosphorylation of STAT3 is carried out by TYK2 in the RA synovium.
In this study, we have also constructed a model on the possible mechanisms by which IFN/IL-10 pathway drive chronic inflammation in the RA synovium. We have found that the expressions of RAC2, an iNOS-interacting protein is consistently up-regulated in the RA synovium.

Table 7. Up-regulation of STAT1 target genes. The number of the synovial datasets in which the STAT1--target genes are up-regulated.

| Gene       | 1 | 2 | 3 | 4 | 5 | 6 |
|------------|---|---|---|---|---|---|
| STAT1      |   |   |   |   |   |   |
| GBP1       |   |   |   |   |   |   |
| ZC3HAV1    |   |   |   |   |   |   |
| GCH1       |   |   |   |   |   |   |
| BAK1       |   |   |   |   |   |   |
| ABCC4      |   |   |   |   |   |   |
| APOL1      |   |   |   |   |   |   |
| CTSS       |   |   |   |   |   |   |
| CXCL10     |   |   |   |   |   |   |
| CXCL9      |   |   |   |   |   |   |
| GBP2       |   |   |   |   |   |   |
| CYP1B1     |   |   |   |   |   |   |
| BCL2L11    |   |   |   |   |   |   |
| GBP5       |   |   |   |   |   |   |
| ICAM1      |   |   |   |   |   |   |
| IFI16      |   |   |   |   |   |   |
| IL7        |   |   |   |   |   |   |
| IRF1       |   |   |   |   |   |   |
| IRF7       |   |   |   |   |   |   |
| IRF9       |   |   |   |   |   |   |
| ITK        |   |   |   |   |   |   |
| LYN        |   |   |   |   |   |   |
| NMI        |   |   |   |   |   |   |
| PSMB8      |   |   |   |   |   |   |
| PSMB9      |   |   |   |   |   |   |
| SH3KBP1    |   |   |   |   |   |   |
| SOD2       |   |   |   |   |   |   |
| STAT2      |   |   |   |   |   |   |
| TAP1       |   |   |   |   |   |   |
| TAP2       |   |   |   |   |   |   |
| AIM2       |   |   |   |   |   |   |
| CIITA      |   |   |   |   |   |   |
| HLA-E      |   |   |   |   |   |   |
| IDO1       |   |   |   |   |   |   |
| C3         |   |   |   |   |   |   |
| MX1        |   |   |   |   |   |   |
| RNF19B     |   |   |   |   |   |   |
| APOL3      |   |   |   |   |   |   |
| IFI35      |   |   |   |   |   |   |
| WARS       |   |   |   |   |   |   |
| TGM2       |   |   |   |   |   |   |

doi:10.1371/journal.pone.0161306.t007
synovium. Interestingly, RAC1/RAC2 was identified to be an important hub in the analysis of the molecular interaction network of RA [18]. In this study, we have described the mechanism by which the STAT1 mediated RAC2 activation can lead to chronic inflammation in the RA synovium via an over-production of NO.

**Conclusion**

In this study, a cytokine signalling network for the regulation of iNOS is created for the first time. From the results of the microarray data analysis on RA synovial datasets, we observed that the most of the genes from IFN- and IL-10 pathways regulating iNOS expression are always up-regulated whereas many genes from the TGF-β anti-inflammatory pathway are down-regulated. The transcription factor STAT1 is up-regulated in both the RA synovium and the synovial macrophages. It is concluded that STAT1 is also influencing the production of NO in the RA synovium by regulating iNOS interaction with RAC2. A model of IFN-γ/IL-10 pathway mediated chronic inflammation via elevated levels of NO in the RA synovium has been constructed.

**Supporting Information**

S1 Fig. The cytokine signalling network regulating expression of iNOS.
(TIF)

S2 Fig. The activation of NF-κB by TNF-α, IL-1β, IFN-γ and TGF-β.
(TIF)

S3 Fig. The regulation of STAT1 phosphorylation at Y701 by TGF-β and the intermediate kinases of IFN.
(TIF)

S4 Fig. The activation of STAT1 phosphorylation at S727 by IFN-γ, IL-1β and TNF-α.
(TIF)

S5 Fig. The activation of STAT1, STAT3 and STAT6 by IL-10, IL-6 and IL-4.
(TIF)

S6 Fig. The activation of Smad proteins by TGF-β.
(TIF)

S7 Fig. The activation of p300, C/EBPβ, AP-1 and Oct-1 by IFN-γ, TNF-α and IL1-β.
(TIF)

S1 File. Search terms used in PubMed for the retrieval of references used to construct the cytokine signalling network.
(DOCX)

S2 File. Description of the cytokine signalling network regulating iNOS expression.
(DOCX)

**Acknowledgments**

We thank Dr. Bibha Choudhary for her critical comments and suggestions at various stages of the analysis. The critical reading of the manuscript and corrections suggested by Dr. Gayatri Saberwal are gratefully acknowledged. We thank Professor N. Yathindra, the director of IBAB,
for his constant encouragement and support. We acknowledge IBAB for providing facilities and environment for this research work.

**Author Contributions**

Conceived and designed the experiments: SR.

Performed the experiments: PD.

Analyzed the data: PD VP.

Contributed reagents/materials/analysis tools: SR.

Wrote the paper: PD VP SR.

**References**

1. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007; 7 (6): 429–442. PMID: 17525752

2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011; 365: 2205–2219. doi: 10.1056/NEJMra1004965 PMID: 22150039

3. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee C, Akbar AN et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Research & Therapy. 2005; 7:R784–R795.

4. Cascão R, Moura RA, Perpétuo I, Canhão H, Vieira-Sousa E, Mourão AF et al. Identification of a cytokine network sustaining neutrophil and Th17, activation in untreated early rheumatoid arthritis. Arthritis Research & Therapy. 2010; 12:R196.

5. Paramalingam SS, Thumboo J, Vasoo S, Thio ST, Tse C, Fong K. In vivo pro- and anti-inflammatory cytokines in normal and patients with rheumatoid arthritis. Ann Acad Med Singapore. 2007; 36(2):96–9. PMID: 17364074

6. Kokkonen H, Söderström I, Rocklöv J, Hallmans G, Lejon K, Dahlqvist SR. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010; 62(2):383–91. doi: 10.1002/art.27186 PMID: 20112361

7. Avramescu C, Vere CC, Mărgăritescu C, Turculeanu A, Bălășoiu M, Rogoz S. Cytokinin panel in rheumatoid arthritis and correlation with histological patterns of synovitis–active type of disease. Rom J Morphol Embryol. 2005; 46(2): 87–92. PMID: 16286991

8. Fearon U, Reece R, Smith J, Emery P, Veale DJ. Synovial cytokine and growth factor regulation of MMPs/ TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann N Y Acad Sci. 1999; 878: 619–21. PMID: 10415789

9. Grabowski PS, Wright PK, Vain-Hof RJ, Helfrich MH, Ohshima H, Ralston SH. Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis. Br J of Rheumatol. 1997; 36(6):651–5.

10. Sakanari H, Kohsaka H, Ming-Fei L, Higashiyama H, Hirata Y, Kanno K et al. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J. Clin. Invest. 1995; 96(5): 2357–63. PMID: 7593623

11. Farrell AJ, Blake DR, Palmer RM, Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis. 1992; 51(11):1219–22. PMID: 1466599

12. Ueki Y, Miyake S, Tominaga Y, Eguchi K. Increased nitric oxide levels in patients with rheumatoid arthritis. J Rheumatol. 1996; 23(2):230–6. PMID: 8882024

13. Akta f F. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004; 75(6):639–653. PMID: 15172174

14. Grabowski PS, Macpherson H, Ralston SH. Nitric Oxide production in the cells derived from the human joint. Br J Rheumatol. 1996; 35(3):207–212. PMID: 8620293

15. Werner F, Jain MK, Feinberg MW, Sibinga NES, Pellacani A, Wiesel P et al. Transforming Growth Factor-β1 Inhibition of Macrophage Activation Is Mediated via Smad3. J Biol Chem. 2000; 275(47):36653–36658. PMID: 10973958
16. Coccia EM, Stellacci E, Marziali G, Weiss G, Battistini A. IFN-γ and IL-4 differently regulate inducible NO synthase gene expression through IRF-1 modulation. Int Immunol. 2000; 12(7): 977–985. PMID: 10882409

17. Kaur J, Syngle A, Krishan P, Vohra K, Garg N, Kaur L et al. IL-6 inhibition improves nitric oxide in rheumatoid arthritis. IJRCI. 2014; 2(1):OA 2.

18. Wu G, Zhu L, Dent JE, Nardini C. A comprehensive molecular interaction map for rheumatoid arthritis. PLoS One. 2010; 5(4):e10137. doi: 10.1371/journal.pone.0010137 PMID: 20419126

19. Kröncke KD, Fehsel K, Kolb-Bachofen V. Inducible nitric oxide synthase in human diseases. Clin Exp Immunol. 1998; 113(2):147–156. PMID: 9717962

20. Borderie D, Hilliquin P, Hernvann A, Lemarchal H, Kahan A, Menkes CJ et al. Inhibition of inducible NO Synthase by TH2 cytokines and TGF-β in rheumatoid arthritis synoviocytes: effects onNitrosothiol production. Nitric Oxide. 2002; 6(3), 271–282. PMID: 12009845

21. Ramana CV, Chatterjee-Kishore M, Nguyen H, Stark GR. Complex roles of Stat1 in regulating gene expression. Oncogene. 2000; 19(21): 2619–27. PMID: 10851061

22. Xu D, Qu CK. Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci. 2008; 13: 4925–4932. PMID: 18508557

23. Niemand C, Nimmesgern A, Haan S, Fischer P, Schaper F, Rossaint R et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol. 2003; 170: 3263–3272. PMID: 12626585

24. Lawrence T. The nuclear factor NF-κB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009; 1(6):a001651. doi: 10.1101/cshperspect.a001651 PMID: 20457564

25. Kleinert H, Schwarz PM, Förstermann U. Regulation of the expression of inducible nitric oxide synthase. Biol. Chem. 2003; 384(10–11), 1343–1364. PMID: 14669979

26. Pohlers D, Beyer A, Koczcan D, Wilhelm T, Thiesen HJ, Kinne RW. Constitutive upregulation of the transforming growth factor-β pathway in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther. 2007, 9(3): R59. PMID: 17594488

27. Habelhah H. Emerging complexity of protein ubiquitination in the NF-κB pathway. Genes & Cancer 2010; 1(7): 735–747.

28. Tarantini N, Timez J-Y, Crowell EF, Boisson B, Henriques R, Mhlanga M, et al. TNF and IL-1 exhibit distinct ubiquitin requirements for inducing NEMO-IKK supramolecular structures. J. Cell Biol. 2014; Vol. 204 No. 2: 231–245. doi: 10.1083/jcb.201307172 PMID: 24446482

29. Kishida S, Sanjo H, Akira S, Matsumoto K, Ninomiya-Tsujii J. TAK1-binding protein 2 facilitates ubiquitination of TRAF6 and assembly of TRAF6 with IKK in the IL-1 signaling pathway. Genes Cells. 2005 May; 10 (5): 447–454. PMID: 15836773

30. Deb A, Haque SJ, Mogensen T, Silverman RH, Williams BRG. RNA-Dependent protein kinase PKR is required for activation of NF-κB by IFN-γ in a STAT1-independent pathway. J Immunol. 2001; 166: 6170–6180. PMID: 11342633

31. Park KS, Guo Z, Shao L, Du Q, Geller DA. A far upstream Oct-1 motif regulates cytokine-induced transcription of the human inducible nitric oxide synthase (hiNOS) gene. J Mol Biol. 2009 July; 390(4): 595–603. doi: 10.1016/j.jmb.2009.05.036 PMID: 19467240
Yarilina A, Park-Min KH, Antoniv T, Hu X, Ivashkiv LB. TNF activation requires an IRF1-dependent autocrine loop. Mol Endocrinol. 2017; 31(6): 1093-1105. doi: 10.1282/jbn.160095 PMID: 28235321

Zhu X, Wu Z, Xu LZ, Darnell JE Jr. STAT1 serine phosphorylation occurs independently of tyrosine phosphorylation and requires an activated Jak2 kinase. Mol Cell Biol. 1997; Vol 19, No. 11: 6618–6623.

Nguyen H, Chatterjee-Kishore M, Jiang Z, Qing Y, Ramana CV, Bayes J et al. IRAK-dependent phosphorylation of Stat1 on serine 727 in response to interleukin-1 and effects on gene expression. J Interferon Cytokine Res. 2003; 23: 183–192. PMID: 12856330

Lee S, Nishino M, Mazumdar T, Garcia GE, Gallione M, Lee FL et al. 16-kDa prolactin down-regulates inducible nitric oxide synthase expression through inhibition of the signal transducer and activator of transcription 1/IFN regulatory factor-1 pathway. Cancer Res. 2005; 65: (17).

Kovarik P, Stoiber D, Eyers PA, Menghini R, Neininger A, Gaestel M et al. Stress-induced phosphorylation of Stat1 at ser727 requires p38 mitogen-activated protein kinase whereas IFN-γ uses a different signaling pathway. PNAS. 1999; Vol 96, No 24: 13956–13961. PMID: 10570180

Gao Q, Liu Y, Wu Y, Zhao Q, Wang L, Gao Q et al. IL-17 intensifies IFN-γ-induced NOS2 upregulation in RAW264.7 cells by further activating STAT1 and NF-κB. Int J Mol Med. 2016; 37: 347–358. doi: 10.3892/ijmm.2015.2433 PMID: 26677135

Xiong H, Zhu C, Li H, Chen F, Mayer L, Ozato K et al. Complex formation of the interferon (IFN) consensus sequence-binding protein with IRF-1 is essential for murine macrophage IFN-γ-induced iNOS gene expression. J Biol Chem. 2003; Vol 278, No. 4: 2271–2277. PMID: 12429737

Lo H, Hsu S, Ali-Syed M, Gunduz M, Xia W, Wei Y et al. Nuclear interaction of EGFR and STAT3 in the activation of the INOS/NO pathway. Cancer Cell. 2005; Vol 7: 575–589. PMID: 15950906

Yu Z, Zhang W, Kone BC. Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the interferon inducing cytokine interleukin-4. Biochem. J. 2002; 367, 97–105. PMID: 12057007

Hiroi M, Sakaeda Y, Yamaguchi H, Ohmori Y. Anti-inflammatory cytokine interleukin-4 inhibits inducible nitric oxide synthase gene expression in the mouse macrophage cell line RAW264.7 through the repression of octamer-dependent transcription. Mediators Inflamm. 2013; 2013: 369693. doi: 10.1155/2013/369693 PMID: 24459328

Chan ED, Winston BW, Uh ST, Wynes MW, Rose DM, Riches DWH. Evaluation of the role of mitogen-activated protein kinases in the expression of inducible nitric oxide synthase by IFN-γ and TNF-α in mouse macrophages. J Immunol. 1999; 162: 415–422. PMID: 9886415

R project for statistical computing [https://www.r-project.org/].

Ungethuem U, Haeupl T, Witt H, Koczcan D, Krenn V, Huber H et al. Molecular signatures and new candidates to target the pathogenesis of rheumatoid arthritis. Physiol Genomics. 2010; 42A (4): 267–82. doi: 10.1152/physiolgenomics.00004.2010 PMID: 20858714

Huber R, Hummer C, Gausmann U, Pohlers D, Koczcan D, Guthke R et al. Identification of intra-group, inter-individual, and gene-specific variances in Mrna expression profiles in the rheumatoid arthritis synovial membrane. Arthritis Res Ther. 2008; 10(4):R98. doi: 10.1186/ar2485 PMID: 18721452

Woetzel D, Huber R, Kupfer P, Pohlers D, Pfaff M, Driesch D et al. Identification of rheumatoid arthritis and osteoarthritis patients by transcriptome-based rule set generation. Arthritis Research & Therapy. 2014; 16: R84.

Yarilina A, Park-Min KH, Antoniv T, Hu X, Ivashkiv LB. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat Immunol. 2008; 9(4): 378–87. doi: 10.1038/ni1576 PMID: 18345002

Van der Pouw Kraan TC, van Gaalen FA, Kasperkowitz PV, Verbeet NL, Smeets TJ, Kraan MC et al. Rheumatoid Arthritis is a heterogeneous disease: Evidence for differences in the activation of the STAT1 pathway between rheumatoid tissues. Arthritis Rheum. 2003; 48(8):2132–2145. PMID: 12905466

Keshava PTS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S et al. Human Protein Reference Database–2009 update. Nucleic Acids Res. 2009; 37 (Database issue): D767–72. doi: 10.1093/nar/gkn892 PMID: 18988627
58. Breuer K, Foroushani AK, Laird MR, Chen C, Sribnaia A, Lo R et al. InnateDB: systems biology of innate immunity and beyond–recent updates and continuing curation. Nucleic Acids Res. 2013; 41 (Database issue): D1228–D1233. doi: 10.1093/nar/gks1147 PMID: 23180781

59. Cerami EG, Gross BE, Demir E, Rodchenkov I, Babur O, Anwar N et al. Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res. 2011; 39 (Database issue): D685–90. doi: 10.1093/nar/gkq1039 PMID: 21071392

60. Hu Y, Hu X, Bomsell L, Ivashkiv LB. IFN-γ and STAT1 arrest monocyte migration and modulate RAC/CDC42 pathways. J. Immunol. 2008; 180(12): 8057–8065. PMID: 18523269

61. Li B, Yu H, Zheng W, Voll R, Na S, Roberts AW et al. Role of the guanosine triphosphatase Rac2 in T helper 1 cell differentiation. Science. 2000; 288(5474): 2219–22. PMID: 10864872

62. Jyoti A, Singh AK, Dubey M, Kumar S, Saluja R, Keshari RS et al. Interaction of inducible nitric oxide synthase with Rac2 regulates reactive oxygen and nitrogen species generation in the human neutrophil phagosomes: implication in microbial killing. Antiox Redox Signal. 2014; 20(3):417–31.

63. Kuncewicz T, Balakrishnan P, Snuggs MB, Kone BC. Specific association of nitric oxide synthase-2 with Rac isoforms in activated murine macrophages. Am. J. Physiol. Renal Physiol. 2001; 281(2): F326–F336. PMID: 11457725

64. Nagy G, Clark JM, Buzás EI, Gorman CL, Cope AP. Nitric oxide, chronic inflammation and autoimmunity. Immunol Lett. 2007; 111(1):1–5. PMID: 17568690

65. Abramson SB. Osteoarthritis and nitric oxide. Osteoarthritis Cartilage. 2008; 16 Suppl 2: S15–20. doi: 10.1016/S1020-3149(08)60008-4 PMID: 18794013

66. Ivashkiv LB, Hu X. The JAK/STAT pathway in rheumatoid arthritis: Pathogenic or protective? Arthritis Rheumatol. 2003; Vol 48, No. 8: 2092–96.

67. Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol. 2005; Vol 32, No. 9: 1650–53. PMID: 16142855

68. Isomäki P, Alaña T, Isohanni P, Lagerstedt A, Korpela M, Moilanen T et al. The expression of SOCS is altered in rheumatoid arthritis. Rheumatology. 2007; 46 (10): 1538–46. PMID: 17726036

69. Chen E, Keystone EC, Fish EN. Restricted cytokine expression in rheumatoid arthritis. Arthritis Rheumatol. 1993; 36 (7): 901–910.

70. Dayer JM, Ernest C. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology. 2010; 49: 15–24. doi: 10.1093/rheumatology/kep329 PMID: 19854855

71. Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010; 2 (5): 247–56. doi: 10.1177/1759720X10378372 PMID: 22870451

72. Hu X, Herrero C, Li WP, Antoniv TT, Falck-Pedersen E, Koch AE et al. Sensitization of IFN-γ Jak-STAT signaling during macrophage activation. Nat Immunol. 2002: 3: 859–866. PMID: 12172544